Review

rabbit polyclonal anti p2y1r antibody (Alomone Labs)

Alomone Labs is a verified supplier

Alomone Labs manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Alomone Labs rabbit polyclonal anti p2y1r antibody
Rabbit Polyclonal Anti P2y1r Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/polyclonal+anti+p2y1+antibody/Anti-P2Y1+Receptor+Antibody/pm41034045-33-10-24
Average 95 stars, based on 70 article reviews

rabbit polyclonal anti p2y1r antibody - by Bioz Stars, 2026-11

95/100 stars

Images

other:

Article Title: A complementary role for tetraspanin superfamily member CD151 and ADP purinergic P2Y12 receptor in platelets
Article Snippet: Mohammed Makkawi1,2; Fatemeh Moheimani1; Raed Alserihi1; David Howells3; Mark Wright4; Leonie Ashman5; Denise E. Jackson1 1Thrombosis and Vascular Diseases Laboratory, Health Innovations Research Institute, RMIT University, Victoria, Australia; 2Department of Pathology, The University of Melbourne, Melbourne, Victoria, Australia; 3Neuroscience Laboratory, Department of Medicine, Austin Health, Heidelberg, Victoria, Australia; 4Department of Immunology, Monash University, Melbourne, Victoria, Australia; 5School of Biomedical Sciences,, University of Newcastle, Newcastle, New South Wales, Australia

Control:

Article Title: Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes.
Article Snippet: Fluorescence was measured with a Perkin-Elmer fluorometer (Perkin-Elmer Ltd., Beaconsfield, UK). .. Polyclonal anti-P2Y1 antibody (0.6 mg/ml) including its control antigen was obtained from Alomone Laboratories (Jerusalem, Israel), and was finally used at a 80-fold dilution. .. Ca2þ concentra- tion was calculated using the FLwinlab software (Perkin-Elmer) (Grynkiewicz et al., 1985).

Image Search Results

Fig. 3 Change in inflammatory gene expression and pathway analysis. (a). Top 20 significant canonical pathways of the core analysis in IPA of most highly expressed genes in OGD astro cytes treated with P2Y1R-ANT (1 mM) and MCM relative to OGD astrocytes. Blue bars: negative z-score; orange bars: positive z-score; gray bars: no activity pattern available; white bars: activity of zero. (b), (c). Heatmap of mRNA-related Neuroinflam mation Signaling expression, and quantitative analysis of representative mRNA-related Neuroinflammation Signaling in OGD astrocytes, OGD astrocytes treated with P2Y1R-ANT (1 mM), and OGD astrocytes treated with P2Y1R-ANT (1 mM) and MCM. *P < 0.05 vs. OGD astro cyte, #P < 0.05 vs. OGD astro cytes treated with P2Y1R-ANT. (d). Signaling pathway predicted by analyzing changes using IPA software in mRNA expression in the OGD astrocytes treated with P2Y1R-ANT and MCM relative to OGD astrocytes, or OGD astrocytes treated with P2Y1R-ANT. The functional networks were generated via IPA (QIAGEN Inc., https://www. qiagenbio-informatics.com/prod ucts/ingenuity-pathway-analysis). N = 4/group. Values are the mean ± SD. IPA = Ingenuity Pathway Analy sis, P2Y1R-ANT = P2Y1 receptor antagonist, MCM = microg lial conditioned medium, MAPK = mitogen-activated protein kinase, NF-κB = nuclear factor-κβ, TNF-α = tumor necro sis factor, IL-1β = interleukin-1β, NOX = nitrogen oxides, CASP8 = Caspase 8

Journal: Molecular neurobiology

Article Title: Astrocytic Extracellular Vesicles Regulated by Microglial Inflammatory Responses Improve Stroke Recovery.

doi: 10.1007/s12035-023-03629-9

Figure Lengend Snippet: Fig. 3 Change in inflammatory gene expression and pathway analysis. (a). Top 20 significant canonical pathways of the core analysis in IPA of most highly expressed genes in OGD astro cytes treated with P2Y1R-ANT (1 mM) and MCM relative to OGD astrocytes. Blue bars: negative z-score; orange bars: positive z-score; gray bars: no activity pattern available; white bars: activity of zero. (b), (c). Heatmap of mRNA-related Neuroinflam mation Signaling expression, and quantitative analysis of representative mRNA-related Neuroinflammation Signaling in OGD astrocytes, OGD astrocytes treated with P2Y1R-ANT (1 mM), and OGD astrocytes treated with P2Y1R-ANT (1 mM) and MCM. *P < 0.05 vs. OGD astro cyte, #P < 0.05 vs. OGD astro cytes treated with P2Y1R-ANT. (d). Signaling pathway predicted by analyzing changes using IPA software in mRNA expression in the OGD astrocytes treated with P2Y1R-ANT and MCM relative to OGD astrocytes, or OGD astrocytes treated with P2Y1R-ANT. The functional networks were generated via IPA (QIAGEN Inc., https://www. qiagenbio-informatics.com/prod ucts/ingenuity-pathway-analysis). N = 4/group. Values are the mean ± SD. IPA = Ingenuity Pathway Analy sis, P2Y1R-ANT = P2Y1 receptor antagonist, MCM = microg lial conditioned medium, MAPK = mitogen-activated protein kinase, NF-κB = nuclear factor-κβ, TNF-α = tumor necro sis factor, IL-1β = interleukin-1β, NOX = nitrogen oxides, CASP8 = Caspase 8

Article Snippet: The primary antibodies used in this study were rabbit polyclonal anti-ionized calcium-binding adapter molecule 1 (Iba-1) (1:800; Wako), mouse monoclonal anti-glial fibrillary acidic protein (GFAP) (1:200; MBL), goat polyclonal anti-GFAP (1:200; Abcam), goat polyclonal anti-C3d (1:25, R&D Systems), rabbit polyclonal anti-S100A10 (1:50, Proteintech), rabbit polyclonal anti-P2Y1 receptor antibody (1:100, Alomone Labs), rabbit polyclonal anti-nuclear factor-κβ (NFκB) (1:200; Abcam), mouse monoclonal anti-TNF-α (1:200; GeneTex), mouse monoclonal pNFH (SMI31)(1:200; BioLegend), and mouse MAP2 (1:500; Merck).

Techniques: Gene Expression, Analysis, Activity Assay, Expressing, Software, Functional Assay, Generated, Oxides, Significance Assay

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: P2Y receptors and nucleotide agonists.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques:

P2Y Gi receptor mRNA levels are regulated in response to inflammatory injury . A ) Amplification of DRG cDNA by conventional RT-PCR using the P2Y Gi real-time PCR primers produced a single band for each receptor of the expected size (100-150 bp). B ) Real-time PCR was used to analyze mRNA levels for each of the Gi-coupled P2Y receptors and the Gq-coupled P2Y1 at 1, 4 and 15 days after induction of inflammatory hyperalgesia by injection of complete Freund's adjuvant into the hindpaw. The shaded box indicates the period of significant heat hyperalgesia determined using the Hargreaves test. Data are normalized against baseline values. *p < 0.01, ‡ p < 0.05, For PCR, n = 5 mice/time point. For behavior, n = 10 mice/time point.

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: P2Y Gi receptor mRNA levels are regulated in response to inflammatory injury . A ) Amplification of DRG cDNA by conventional RT-PCR using the P2Y Gi real-time PCR primers produced a single band for each receptor of the expected size (100-150 bp). B ) Real-time PCR was used to analyze mRNA levels for each of the Gi-coupled P2Y receptors and the Gq-coupled P2Y1 at 1, 4 and 15 days after induction of inflammatory hyperalgesia by injection of complete Freund's adjuvant into the hindpaw. The shaded box indicates the period of significant heat hyperalgesia determined using the Hargreaves test. Data are normalized against baseline values. *p < 0.01, ‡ p < 0.05, For PCR, n = 5 mice/time point. For behavior, n = 10 mice/time point.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques: Amplification, Reverse Transcription Polymerase Chain Reaction, Real-time Polymerase Chain Reaction, Produced, Injection

ADP evokes Ca ++ transients through P2Y1.

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: ADP evokes Ca ++ transients through P2Y1.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques:

P2Y Gi agonists inhibit depolarization-evoked increases in intracellular Ca ++ . Fura-2 Ca ++ imaging was used to measure the effect of P2Y receptor agonists on Ca ++ transients evoked by administration of 50 mM K + . Application of ADP (100 μM) for 3 minutes reduced subsequent depolarization-evoked transients in wildtype ( A ) and P2Y1-/- ( B ) mice. The P2Y13 agonist IDP ( C ) and the P2Y14 agonist UDPG ( D ) also inhibited depolarization-evoked transients.

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: P2Y Gi agonists inhibit depolarization-evoked increases in intracellular Ca ++ . Fura-2 Ca ++ imaging was used to measure the effect of P2Y receptor agonists on Ca ++ transients evoked by administration of 50 mM K + . Application of ADP (100 μM) for 3 minutes reduced subsequent depolarization-evoked transients in wildtype ( A ) and P2Y1-/- ( B ) mice. The P2Y13 agonist IDP ( C ) and the P2Y14 agonist UDPG ( D ) also inhibited depolarization-evoked transients.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques: Imaging

Extent of inhibition by P2Y Gi receptor agonists.

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: Extent of inhibition by P2Y Gi receptor agonists.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques: Inhibition

The inhibitory effect of ADP is enhanced in the absence of P2Y1 signaling . The magnitudes of depolarization-evoked Ca ++ transients in sensory neurons were measured before, and 5, 10 and 15 minutes after agonist application. Ca ++ transients were not affected by application of buffer alone (dashed lines), but were significantly reduced after application of ADP ( A-B ), IDP ( C ), or UDPG ( D ; solid lines). Inhibition was prolonged by application of the selective P2Y1 antagonist MRS2179 ( A ) and in neurons from P2Y1-/- mice ( B ). There was no effect of MRS2179 in P2Y1-/- neurons ( B ). Values are mean ± SEM; n = 10 mice/timepoint each treatment. *p < 0.02 versus control for each treatment.

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: The inhibitory effect of ADP is enhanced in the absence of P2Y1 signaling . The magnitudes of depolarization-evoked Ca ++ transients in sensory neurons were measured before, and 5, 10 and 15 minutes after agonist application. Ca ++ transients were not affected by application of buffer alone (dashed lines), but were significantly reduced after application of ADP ( A-B ), IDP ( C ), or UDPG ( D ; solid lines). Inhibition was prolonged by application of the selective P2Y1 antagonist MRS2179 ( A ) and in neurons from P2Y1-/- mice ( B ). There was no effect of MRS2179 in P2Y1-/- neurons ( B ). Values are mean ± SEM; n = 10 mice/timepoint each treatment. *p < 0.02 versus control for each treatment.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques: Inhibition

ADP has opposing effects on behavioral nociceptive thresholds in the presence and absence of P2Y1 . ADP has opposite effects on withdrawal latencies to noxious heat stimuli (Hargreaves test) in the presence and absence of P2Y1. A) P2Y1-/- mice show a deficit in thermal hyperalgesia at day 3 following CFA injection, compared to wildtype mice. B) Injection of ADP into the hindpaw of naïve mice caused thermal hyperalgesia in wildtype mice, but hypoalgesia in P2Y1-/- mice. C) Mice were injected with ADP in the hindpaw three days after CFA injection and thermal response thresholds were measured. ADP injection had no effect on thermal thresholds in inflamed wildtype mice, but reversed thermal hyperalgesia in P2Y1-/- mice. D) Hindpaw injection of MRS2500, a P2Y1 antagonist, in inflamed wildtype mice acutely reversed thermal hyperalgesia compared to saline injection. Injection of either IDP ( E ) or UDPG ( F ) into the inflamed hindpaw reversed inflammation-evoked thermal hyperalgesia. n = 10 mice/cohort.

Journal: Molecular Pain

Article Title: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior

doi: 10.1186/1744-8069-6-21

Figure Lengend Snippet: ADP has opposing effects on behavioral nociceptive thresholds in the presence and absence of P2Y1 . ADP has opposite effects on withdrawal latencies to noxious heat stimuli (Hargreaves test) in the presence and absence of P2Y1. A) P2Y1-/- mice show a deficit in thermal hyperalgesia at day 3 following CFA injection, compared to wildtype mice. B) Injection of ADP into the hindpaw of naïve mice caused thermal hyperalgesia in wildtype mice, but hypoalgesia in P2Y1-/- mice. C) Mice were injected with ADP in the hindpaw three days after CFA injection and thermal response thresholds were measured. ADP injection had no effect on thermal thresholds in inflamed wildtype mice, but reversed thermal hyperalgesia in P2Y1-/- mice. D) Hindpaw injection of MRS2500, a P2Y1 antagonist, in inflamed wildtype mice acutely reversed thermal hyperalgesia compared to saline injection. Injection of either IDP ( E ) or UDPG ( F ) into the inflamed hindpaw reversed inflammation-evoked thermal hyperalgesia. n = 10 mice/cohort.

Article Snippet: Primary antibodies used were rabbit polyclonal anti-P2Y1 (Alomone), anti-P2Y12 (Alomone; 1:200), anti-P2Y13 (Novus; 1:300) and anti-P2Y14 (Affinity Bioreagents; 1:2000).

Techniques: Injection

Figure 3. Endothelial P2Y2R-TRPV4 channel signaling lowers pulmonary artery (PA) contractility and pulmonary arterial pressure (PAP). (A) Left: immunofluorescence images of en face fourth-order PAs from P2ry2fl/fl and P2ry2 cKO-EC mice. CD31 immunofluorescence indicates ECs. Right: effects of ATP (1 μmol/L) on TRPV4EC sparklet activity in the absence or presence of the P2Y1R inhibitor MRS2179 (MRS; 10 μmol/L) or P2Y2R inhibitor AR-C 118925XX (AR-C; 10 μmol/L) in PAs from P2ry2fl/fl and P2ry2 cKO-EC mice, expressed as NPO per site (n = 5; ***p<0.001 vs. Control [- ATP]; **p<0.01 vs.+ MRS [- ATP]; ns indicates no statistical significance; two-way ANOVA). ‘N’ is the number of channels per site and ‘PO’ is the open state probability of the channel. (B) Effects of ATP (1 μmol/L) on TRPV4EC sparklet activity in the presence of the general P2X1-5/7R inhibitor PPADS (10 μmol/L) and P2X7 R inhibitor JNJ-47965567 (JNJ; 1 μmol/L) in PAs of C57BL6/J mice (n = 5; *p<0.05 vs. [-ATP]; one-way ANOVA). (C) Top: representative ATP (10 μmol/L)- induced outward TRPV4 currents in freshly isolated ECs from C57BL6/J mice and the effect of GSK2193874 (GSK219; TRPV4 inhibitor; 100 nmol/L) in the presence of ATP. Currents were elicited by a 200 ms voltage step from –50 mV to +100 mV. Bottom: scatterplot showing outward currents at +100 mV under baseline conditions, after the addition of ATP, and after the addition of GSK219 (100 nmol/L; n = 6 cells; ***p<0.001 vs. baseline; **p<0.01 vs.+ ATP [10 μmol/L]; one-way ANOVA). (D) Left: representative traces showing TRPV4EC sparklet activity in en face preparations of PAs from P2ry2fl/fl mice. Dotted lines are quantal levels. Right: TRPV4EC sparklet activity per site (NPO) in en face preparations of PAs from P2ry2fl/fl and P2ry2 cKO-EC mice under baseline conditions (i.e., 20 μmol/L cyclopiazonic acid [CPA]) and in response to 2-thio UTP (P2Y2R agonist, 0.5 μmol/L; n = 5; *p<0.05 vs. P2ry2fl/fl [-2-thio UTP]; ns indicates no statistical significance; t-test). (E) Left: average resting right ventricular systolic pressure (RVSP) values in P2ry2fl/fl and P2ry2 cKO-EC mice (n = 6; **p<0.01; t-test). Right: average Fulton index values in P2ry2fl/fl and P2ry2 cKO-EC mice (n = 5–6; ns indicates no statistical significance). (F) Right: representative diameter traces showing ATP (1 μmol/L)-induced dilation of PAs from P2ry2fl/fl and P2ry2 cKO-EC mice, pre-constricted with the thromboxane A2 receptor agonist U46619 (U466, 50 nmol/L). Fourth-order PAs were pressurized to 15 mm Hg. Right: percent dilation of PAs from P2ry2fl/

Journal: eLife

Article Title: Endothelial pannexin 1–TRPV4 channel signaling lowers pulmonary arterial pressure in mice

doi: 10.7554/elife.67777

Figure Lengend Snippet: Figure 3. Endothelial P2Y2R-TRPV4 channel signaling lowers pulmonary artery (PA) contractility and pulmonary arterial pressure (PAP). (A) Left: immunofluorescence images of en face fourth-order PAs from P2ry2fl/fl and P2ry2 cKO-EC mice. CD31 immunofluorescence indicates ECs. Right: effects of ATP (1 μmol/L) on TRPV4EC sparklet activity in the absence or presence of the P2Y1R inhibitor MRS2179 (MRS; 10 μmol/L) or P2Y2R inhibitor AR-C 118925XX (AR-C; 10 μmol/L) in PAs from P2ry2fl/fl and P2ry2 cKO-EC mice, expressed as NPO per site (n = 5; ***p<0.001 vs. Control [- ATP]; **p<0.01 vs.+ MRS [- ATP]; ns indicates no statistical significance; two-way ANOVA). ‘N’ is the number of channels per site and ‘PO’ is the open state probability of the channel. (B) Effects of ATP (1 μmol/L) on TRPV4EC sparklet activity in the presence of the general P2X1-5/7R inhibitor PPADS (10 μmol/L) and P2X7 R inhibitor JNJ-47965567 (JNJ; 1 μmol/L) in PAs of C57BL6/J mice (n = 5; *p<0.05 vs. [-ATP]; one-way ANOVA). (C) Top: representative ATP (10 μmol/L)- induced outward TRPV4 currents in freshly isolated ECs from C57BL6/J mice and the effect of GSK2193874 (GSK219; TRPV4 inhibitor; 100 nmol/L) in the presence of ATP. Currents were elicited by a 200 ms voltage step from –50 mV to +100 mV. Bottom: scatterplot showing outward currents at +100 mV under baseline conditions, after the addition of ATP, and after the addition of GSK219 (100 nmol/L; n = 6 cells; ***p<0.001 vs. baseline; **p<0.01 vs.+ ATP [10 μmol/L]; one-way ANOVA). (D) Left: representative traces showing TRPV4EC sparklet activity in en face preparations of PAs from P2ry2fl/fl mice. Dotted lines are quantal levels. Right: TRPV4EC sparklet activity per site (NPO) in en face preparations of PAs from P2ry2fl/fl and P2ry2 cKO-EC mice under baseline conditions (i.e., 20 μmol/L cyclopiazonic acid [CPA]) and in response to 2-thio UTP (P2Y2R agonist, 0.5 μmol/L; n = 5; *p<0.05 vs. P2ry2fl/fl [-2-thio UTP]; ns indicates no statistical significance; t-test). (E) Left: average resting right ventricular systolic pressure (RVSP) values in P2ry2fl/fl and P2ry2 cKO-EC mice (n = 6; **p<0.01; t-test). Right: average Fulton index values in P2ry2fl/fl and P2ry2 cKO-EC mice (n = 5–6; ns indicates no statistical significance). (F) Right: representative diameter traces showing ATP (1 μmol/L)-induced dilation of PAs from P2ry2fl/fl and P2ry2 cKO-EC mice, pre-constricted with the thromboxane A2 receptor agonist U46619 (U466, 50 nmol/L). Fourth-order PAs were pressurized to 15 mm Hg. Right: percent dilation of PAs from P2ry2fl/

Article Snippet: 67777 15 of 26 Reagent type (species) or resource Designation Source or reference Identifiers Additional information Antibody Panx1 (rabbit polyclonal) Alomone Labs Cat. #: ACC-234; RRID:AB_2340917 (1:100) Antibody P2Y2R (rabbit polyclonal) Alomone Labs Cat. #: APR-010; RRID:AB_2040078 (1:250) Antibody P2Y1R (rabbit polyclonal) Alomone Labs Cat. #: APR-009; RRID:AB_2040070 (1:100) Chemical compound, drug GSK2193874 Tocris Bioscience Cat. #: 5106/5 Chemical compound, drug Cyclopiazonic acid (CPA) Tocris Bioscience Cat. #: 1235/10 Chemical compound, drug GSK1016790A Tocris Bioscience Cat. #: 6433/10 Chemical compound, drug Phorbol 12- myristate 13- acetate (PMA) Tocris Bioscience Cat. #: 1201/1 Chemical compound, drug AR- C 118925XX Tocris Bioscience Cat. #: 4890/5 Chemical compound, drug 2- Thio UTP tetrasodium salt Tocris Bioscience Cat. #: 3280/1 Chemical compound, drug MRS2179 Tocris Bioscience Cat. #: 0900/10 Chemical compound, drug U-73122 Tocris Bioscience Cat. #: 1268/10 Chemical compound, drug NS309 Tocris Bioscience Cat. #: 3895/10 Chemical compound, drug ARL-67156 Tocris Bioscience Cat. #: 1283/10 Other Fluo-4- AM Invitrogen Cat. #: F14201 Chemical compound, drug 1- O- 9Z- octadecenoyl-2- O- acetylsn- glycerol (OAG) Cayman Chemicals Cat. #: 62600 Chemical compound, drug PPADS Cayman Chemicals Cat. #: 14537 Chemical compound, drug Gö-6976 Cayman Chemicals Cat. #: 13310 Chemical compound, drug JNJ-47965567 Cayman Chemicals Cat. #: 21895 Chemical compound, drug U46619 Cayman Chemicals Cat. #: 16452 Chemical compound, drug Tamoxifen Sigma- Aldrich Cat. #: T5648 Peptide, recombinant protein Apyrase Sigma- Aldrich Cat. #: A6535 Software, algorithm LabChart8 ADInstruments https://www.adinstruments. com/products/labchart RRID:SCR_017551 Software, algorithm Segment version 2.0 R5292 Twilio (http:// segment. heiberg. se) Software, algorithm IonOptix IonOptix, LLC ( https://www. ionoptix. com/ products/software/ionwizard-coreand-analysis/) Software, algorithm SparkAn Dr. Adrian Bonev, University of Vermont, Burlington, VT, USA PMID:22556255 Software, algorithm ClampFit10.3 Molecular Devices (https://www. moleculardevices. com/) RRID:SCR_011323 Software, algorithm ImageJ National Institutes of Health (https:// imagej. nih. gov/ ij/) RRID:SCR_003070 Continued on next page Continued Daneva et al. eLife 2021;0:e67777.

Techniques: Immunofluorescence, Activity Assay, Control, Isolation

Primary and secondary antisera and their respective dilutions used for immunohistochemistry on ileal whole-mount preparations.

Journal: Cells

Article Title: Involvement of Enteric Glia in Small Intestine Neuromuscular Dysfunction of Toll-Like Receptor 4-Deficient Mice

doi: 10.3390/cells9040838

Figure Lengend Snippet: Primary and secondary antisera and their respective dilutions used for immunohistochemistry on ileal whole-mount preparations.

Article Snippet: P2Y1 (polyclonal) , Rabbit , 1:50 , APR-009 , Alomone Labs (Jerusalem, Israel).

Techniques: Immunohistochemistry

TLR4 signaling and EGC activity affect P2Y1 receptor-mediated small intestinal relaxation. ( A ) 10 Hz EFS-evoked relaxation in NANC conditions with or without 10 μM FA or 10 μM MRS2500 (P2Y1R inhibitor) in ileal segments of WT and TLR4 −/− mice. ( B ) qRT-PCR quantification of P2Y1R mRNA levels in small intestine segments of WT and TLR4 −/− mice in the presence or absence of 10 μM FA. ( C ) Representative confocal microphotographs showing the distribution of P2Y1R (yellow) and GFAP (cyan) and ( D ) analysis of P2Y1R density index in ileal LMMPs of WT and TLR4 -/- mice in the presence or absence of 10 μM FA (bars = 22 μm). White arrowheads indicate P2Y1 + neurons, stars indicate P2Y1 + glial cell bodies, respectively. Data are reported as mean ± SEM for all panels. ** P < 0.01, *** P < 0.001 vs. WT; ° P < 0.05, °°° P < 0.001 vs. respective control without FA; § P < 0.05, §§ P < 0.01 vs. respective control without MRS2500; ## P < 0.01 vs. respective control with FA and without MRS2500; N = 6 mice/group.

Journal: Cells

Article Title: Involvement of Enteric Glia in Small Intestine Neuromuscular Dysfunction of Toll-Like Receptor 4-Deficient Mice

doi: 10.3390/cells9040838

Figure Lengend Snippet: TLR4 signaling and EGC activity affect P2Y1 receptor-mediated small intestinal relaxation. ( A ) 10 Hz EFS-evoked relaxation in NANC conditions with or without 10 μM FA or 10 μM MRS2500 (P2Y1R inhibitor) in ileal segments of WT and TLR4 −/− mice. ( B ) qRT-PCR quantification of P2Y1R mRNA levels in small intestine segments of WT and TLR4 −/− mice in the presence or absence of 10 μM FA. ( C ) Representative confocal microphotographs showing the distribution of P2Y1R (yellow) and GFAP (cyan) and ( D ) analysis of P2Y1R density index in ileal LMMPs of WT and TLR4 -/- mice in the presence or absence of 10 μM FA (bars = 22 μm). White arrowheads indicate P2Y1 + neurons, stars indicate P2Y1 + glial cell bodies, respectively. Data are reported as mean ± SEM for all panels. ** P < 0.01, *** P < 0.001 vs. WT; ° P < 0.05, °°° P < 0.001 vs. respective control without FA; § P < 0.05, §§ P < 0.01 vs. respective control without MRS2500; ## P < 0.01 vs. respective control with FA and without MRS2500; N = 6 mice/group.

Article Snippet: P2Y1 (polyclonal) , Rabbit , 1:50 , APR-009 , Alomone Labs (Jerusalem, Israel).

Techniques: Activity Assay, Quantitative RT-PCR

Review

rabbit polyclonal anti p2y1r antibody (Alomone Labs)

Structured Review

Images

Related Articles

other:

Control:

Similar Products

Image Search Results